Traumatic brain injury (TBI) is a major health problem in the veteran population. Traditionally, TBI-induced brain damage is thought to be limited to the acute and sub-acute periods after trauma. However, abundant evidence from both human and experimental studies strongly suggests that a single TBI can trigger a progressive, long-term neurodegenerative process. However, the underlying mechanisms are not well understood. Endoplasmic reticulum (ER) stress and abnormal protein accumulation are detected in the acute brain injury following TBI. These changes may contribute to neuronal death in the acute stage of brain injury. Unexpectedly, in our pilot study, we detected prolonged ER stress and unfolded protein response (UPR) activation at 3-21 days after the controlled cortical impact injury. Most importantly, post-TBI administration of docosahexaenoic acid (DHA, 22:6n- 3) attenuated ER stress, abnormal protein accumulation, and ubiquitinated-protein aggregate formation in the injured rat brains. These preliminary findings led us to hypothesize that: 1) TBI triggers sustained ER stress and the UPR activation during the post-injury recovery phase; 2) the prolonged ER stress, abnormal protein accumulation, ubiquitinated-protein aggregate formation, and ER stress-associated inflammation contribute to development of neurological deficits after TBI; 3) DHA may enhance long- term neurological function recovery after TBI, in part, via reducing ER stress and abnormal protein accumulation. These hypotheses will be tested in three Specific Aims:
Aim 1 : To determine a causal link between TBI-mediated chronic ER stress and abnormal protein accumulation and aggregate formation following TBI Aim 2: To investigate whether DHA-mediated inhibition of ER stress leads to reduction of abnormal protein accumulation as well as improved neurological function after TBI Aim 3: To investigate effects of DHA on reduction of ER stress-associated inflammation after TBI To date, there are no effective treatments yet proven to improve the long-term neurological function recovery after TBI. DHA is a nutritional supplement with well-established safety profile and multi-mechanistic neuroprotective properties. The goal of this study is to investigate a newly discovered function of DHA in blocking sustained ER stress, and ER stress-associated inflammation after TBI and its efficacy in improving the long-term neurological function. There have been no clinical trials investigating the effects of DHA dietary supplementation on the treatment or prevention of TBI. A positive outcome from this study, together with other preclinical studies, will further warrant a well- designed clinical trial to determine whether omega-3 polyunsaturated fatty acid supplementation may improve outcomes following mild TBI.

Public Health Relevance

Brain injury resulting from traumatic brain injury (TBI) is a major problem in the veteran population and there are no effective treatments proven to improve long-term recovery. Endoplasmic reticulum (ER) stress has recently received increased attention in neurodegeneration after TBI, cerebral ischemia, Alzheimer's disease, and Parkinson's disease. A prolonged ER stress and unfolded protein response (UPR) activation, and ER stress-associated inflammation may lead to neurodegeneration. Our goal of this study is to investigate whether the prolonged ER dysfunction after TBI would exacerbate the imbalanced regulation of the accumulation of unfolded proteins and protein degradation in TBI brains and to examine the efficacy of docosahexaenoic acid (DHA) in blocking of the prolonged ER stress and ER stress-associated inflammation after TBI and in improving the neurological functions. DHA is a nutritional supplement with well-established safety profiles. Therefore, a positive outcome from this study could be translated into clinical trials for TBI treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS089051-04
Application #
9265524
Study Section
Neural Oxidative Metabolism and Death Study Section (NOMD)
Program Officer
Bellgowan, Patrick S F
Project Start
2014-06-01
Project End
2019-04-30
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Neurology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213